MDT / Medtronic plc - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2026 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2026 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years Disciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years Disciplined execution and portfolio strength position Medtronic for continued momentum into fiscal year 2027 GALWAY, Ireland – June 3, 2026 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) Building Two, Parkmore Business Park West n/a Galway, Ireland (Address of principal exec

Medtronic plc

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2025 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2025 to December 31, 2025 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic statement on unauthorized system access

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic statement on unauthorized system access April 24, 2026 Medtronic has determined that an unauthorized party accessed data in certain Medtronic corporate IT systems. We have not identified any impact to our products, patient safety, connections to our customers, our manufacturing and distribution operations, our financial reporting systems or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 Medtronic plc (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2026 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2026 Medtronic plc (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2026 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

[Signature Page Follows]

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 www.medtronic.com March 9, 2026 Re: Registration Statement on Form S-3 Ladies and Gentlemen: This opinion is furnished to you in connection with a Registration Statement on Form S-3 (the “Registration Statement”) filed by Medtronic, Inc., a Minnesota corporation (the “Company”), Medtronic Public Limited Company, a publi

MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. as Guarantors as Trustee SUBORDINATED INDENTURE Dated as of

EX-4.4 Exhibit 4.4 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer and MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors TO , as Trustee SUBORDINATED INDENTURE Dated as of TABLE OF CONTENTS* Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 10 Section 1.03 Form of Documents Delivered to

As filed with the Securities and Exchange Commission on March 9, 2026

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 9, 2026 Registration No.

MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. as Guarantors as Trustee SUBORDINATED INDENTURE Dated as of

EX-4.4 Exhibit 4.4 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer and MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors TO , as Trustee SUBORDINATED INDENTURE Dated as of TABLE OF CONTENTS* Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 10 Section 1.03 Form of Documents Delivered to

[Remainder of page intentionally left blank – Signature page follows]

EX-5.3 Exhibit 5.3 To: Medtronic Global Holdings S.C.A. 40, avenue Monterey L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 9 March 2026 Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic GP S.à r.l. Dear Sirs, I. Introduction We have been appointed as legal counsel in the Grand Duchy of Luxembourg (“Luxembourg”) by Medtronic Global Holdings S.C.A

MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. as Guarantors as Trustee SUBORDINATED INDENTURE Dated as of

EX-4.4 Exhibit 4.4 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer and MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors TO , as Trustee SUBORDINATED INDENTURE Dated as of TABLE OF CONTENTS* Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 10 Section 1.03 Form of Documents Delivered to

Medtronic Global Holdings S.C.A. Numéro d’immatriculation : 8191129

EX-3.3 Exhibit 3.3 CERTIFIED TRANSLATION THE ORIGINAL AND THE TRANSLATION BEAR THE SAME NUMBER: 910256 The undersigned Luc PETRY, sworn translator registered with the Higher Court of Justice of and in Luxembourg, hereby certifies having verified the present translation “RCS EXTRAIT Medtronic Global Holdings S.C.A.” with a French - English translator. /s/ Luc Petry Sworn translator Page 1 of 7. 24/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

[Signature Page Follows]

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 www.medtronic.com March 9, 2026 Re: Registration Statement on Form S-3 Ladies and Gentlemen: This opinion is furnished to you in connection with a Registration Statement on Form S-3 (the “Registration Statement”) filed by Medtronic, Inc., a Minnesota corporation (the “Company”), Medtronic Public Limited Company, a publi

Security Type

Calculation of Filing Fee Tables S-3 Medtronic plc Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Debt Securities 457(r) 0.

Security Type

Calculation of Filing Fee Tables S-3 Medtronic plc Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Debt Securities 457(r) 0.

Medtronic Global Holdings S.C.A. Société en commandite par actions Siège social: 40 avenue Monterey,L- 2163 Luxembourg Grand-Duché de Luxembourg R.C.S. Luxembourg B191129 CONSOLIDATED ARTICLES OF ASSOCIATION dated 23 April 2025 STATUTS COORDONNES à l

EX-3.4 Exhibit 3.4 Registre de Commerce et des Sociétés Numéro RCS : B191129 Référence de dépôt : L250148678 Déposé et enregistré le 12/05/2025 Medtronic Global Holdings S.C.A. Société en commandite par actions Siège social: 40 avenue Monterey,L- 2163 Luxembourg Grand-Duché de Luxembourg R.C.S. Luxembourg B191129 CONSOLIDATED ARTICLES OF ASSOCIATION dated 23 April 2025 STATUTS COORDONNES à la date

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.3 Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

Medtronic Global Holdings S.C.A. Numéro d’immatriculation : 8191129

EX-3.3 Exhibit 3.3 CERTIFIED TRANSLATION THE ORIGINAL AND THE TRANSLATION BEAR THE SAME NUMBER: 910256 The undersigned Luc PETRY, sworn translator registered with the Higher Court of Justice of and in Luxembourg, hereby certifies having verified the present translation “RCS EXTRAIT Medtronic Global Holdings S.C.A.” with a French - English translator. /s/ Luc Petry Sworn translator Page 1 of 7. 24/

As filed with the Securities and Exchange Commission on March 9, 2026

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 9, 2026 Registration No.

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Michelle Quinn and Brian Sandstrom, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-3 file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.3 Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Michelle Quinn and Brian Sandstrom, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-3 file

Medtronic Global Holdings S.C.A. Numéro d’immatriculation : 8191129

EX-3.3 Exhibit 3.3 CERTIFIED TRANSLATION THE ORIGINAL AND THE TRANSLATION BEAR THE SAME NUMBER: 910256 The undersigned Luc PETRY, sworn translator registered with the Higher Court of Justice of and in Luxembourg, hereby certifies having verified the present translation “RCS EXTRAIT Medtronic Global Holdings S.C.A.” with a French - English translator. /s/ Luc Petry Sworn translator Page 1 of 7. 24/

Medtronic Global Holdings S.C.A. Société en commandite par actions Siège social: 40 avenue Monterey,L- 2163 Luxembourg Grand-Duché de Luxembourg R.C.S. Luxembourg B191129 CONSOLIDATED ARTICLES OF ASSOCIATION dated 23 April 2025 STATUTS COORDONNES à l

EX-3.4 Exhibit 3.4 Registre de Commerce et des Sociétés Numéro RCS : B191129 Référence de dépôt : L250148678 Déposé et enregistré le 12/05/2025 Medtronic Global Holdings S.C.A. Société en commandite par actions Siège social: 40 avenue Monterey,L- 2163 Luxembourg Grand-Duché de Luxembourg R.C.S. Luxembourg B191129 CONSOLIDATED ARTICLES OF ASSOCIATION dated 23 April 2025 STATUTS COORDONNES à la date

[Remainder of page intentionally left blank – Signature page follows]

EX-5.3 Exhibit 5.3 To: Medtronic Global Holdings S.C.A. 40, avenue Monterey L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 9 March 2026 Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic GP S.à r.l. Dear Sirs, I. Introduction We have been appointed as legal counsel in the Grand Duchy of Luxembourg (“Luxembourg”) by Medtronic Global Holdings S.C.A

POWER OF ATTORNEY

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Michelle Quinn and Brian Sandstrom, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-3 file

[Signature Page Follows]

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 www.medtronic.com March 9, 2026 Re: Registration Statement on Form S-3 Ladies and Gentlemen: This opinion is furnished to you in connection with a Registration Statement on Form S-3 (the “Registration Statement”) filed by Medtronic, Inc., a Minnesota corporation (the “Company”), Medtronic Public Limited Company, a publi

Medtronic Global Holdings S.C.A. Société en commandite par actions Siège social: 40 avenue Monterey,L- 2163 Luxembourg Grand-Duché de Luxembourg R.C.S. Luxembourg B191129 CONSOLIDATED ARTICLES OF ASSOCIATION dated 23 April 2025 STATUTS COORDONNES à l

EX-3.4 Exhibit 3.4 Registre de Commerce et des Sociétés Numéro RCS : B191129 Référence de dépôt : L250148678 Déposé et enregistré le 12/05/2025 Medtronic Global Holdings S.C.A. Société en commandite par actions Siège social: 40 avenue Monterey,L- 2163 Luxembourg Grand-Duché de Luxembourg R.C.S. Luxembourg B191129 CONSOLIDATED ARTICLES OF ASSOCIATION dated 23 April 2025 STATUTS COORDONNES à la date

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

[Remainder of page intentionally left blank – Signature page follows]

EX-5.3 Exhibit 5.3 To: Medtronic Global Holdings S.C.A. 40, avenue Monterey L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 9 March 2026 Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic GP S.à r.l. Dear Sirs, I. Introduction We have been appointed as legal counsel in the Grand Duchy of Luxembourg (“Luxembourg”) by Medtronic Global Holdings S.C.A

As filed with the Securities and Exchange Commission on March 9, 2026

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 9, 2026 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.3 Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

Security Type

Calculation of Filing Fee Tables S-3 Medtronic plc Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt Debt Securities 457(r) 0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE

EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 23, 2026 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 23, 2026 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolio GALWAY, Ireland – February 17, 2026 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 24, 2025 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 24, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum Cardiac Ablation Solutions growth of 71% on strength of pulsed field ablation (PFA) portfolio; Raising FY26 revenue and EPS guidance GALWAY, Ireland – November 18, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2025 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K/A (Amendment No. 1) (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K/A (Amendment No. 1) (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the

COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEDTRONIC PUBLIC LIMITED COMPANY (as amended by Special Resolution on 16 October 2025)

COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES CONSTITUTION OF MEDTRONIC PUBLIC LIMITED COMPANY (as amended by Special Resolution on 16 October 2025) M-34254565-1 COMPANIES ACT 2014 A PUBLIC COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF MEDTRONIC PUBLIC LIMITED COMPANY 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

To: Medtronic Global Holdings S.C.A. 40, avenue Monterey, L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 29 September 2025

EX-5.3 Exhibit 5.3 To: Medtronic Global Holdings S.C.A. 40, avenue Monterey, L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 29 September 2025 Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic GP S.à r.l. Dear Sirs, I. Introduction We have been appointed as legal counsel in the Grand Duchy of Luxembourg (“Luxembourg”) in order to provide you with

25-NSE

X0203 0000876661 NEW YORK STOCK EXCHANGE LLC 0001613103 Medtronic plc 001-36820 710 Medtronic Pkwy Minneapolis MN MINNESOTA 55432 (763) 514-4000 Guarantor of 2.625% Senior Notes due 2025 17 CFR 240.12d2-2(a)(1) Tyler Mastronardi Analyst, Market Watch 2025-09-29

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 Medtronic plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic, Inc. (Exact name of registrant as

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic, Inc. (Exact name of registrant as specified in its charter) Minnesota 41-0793183 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the Guarantor of the stated securities from listing and registration on the Exchange at the opening of business on October 10, 2025, pursuant to the provisions of Rule 12d2-2 (a).

[Signature Page Follows]

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 www.medtronic.com September 29, 2025 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic, Inc Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic, Inc., a Minnesota corporation (the “Company”) of €750,000,000 aggregate principal amo

NYSE CERTIFICATION

New York Stock Exchange 11 Wall Street New York, NY 10005 Tel: +1 212.656.3000 nyse.com September 29, 2025 Chief, Information Technology Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE MS 3040 Washington, DC 20549 To whom it may concern: The New York Stock Exchange certifies its approval for listing and registration of the following securities of Medtronic, Inc.,

DATED SEPTEMBER 29, 2025 MEDTRONIC, INC. PAYING AGENT U.S. BANK EUROPE DAC, UK BRANCH TRANSFER AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. - AND - COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATI

EX-4.7 Exhibit 4.7 DATED SEPTEMBER 29, 2025 ISSUER MEDTRONIC, INC. PAYING AGENT U.S. BANK EUROPE DAC, UK BRANCH TRANSFER AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. REGISTRAR U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. - AND - TRUSTEE COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT relating to certain Notes issued under a supplemental indenture dated September 29, 20

MEDTRONIC, INC. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC GLOBAL HOLDINGS S.C.A. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee, U.S. BANK EUROPE DAC, UK BRANCH, as

EX-4.1 Exhibit 4.1 MEDTRONIC, INC. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC GLOBAL HOLDINGS S.C.A. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee, and U.S. BANK EUROPE DAC, UK BRANCH, as Paying Agent SIXTH SUPPLEMENTAL INDENTURE Dated as of September 29, 2025 TO THE INDENTURE Dated as of December 10, 2014 Relatin

Security Type

Calculation of Filing Fee Tables S-3 MEDTRONIC INC Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Debt 2.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 Medtronic plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2025 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numb

€1,500,000,000 MEDTRONIC, INC. €750,000,000 2.950% Senior Notes due 2030 €750,000,000 4.200% Senior Notes due 2045 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC GLOBAL HOLDINGS S.C.A.

424B5 Filed pursuant to Rule 424(b)(5) Registration File No. 333-270272-01 PROSPECTUS SUPPLEMENT (To Prospectus dated March 3, 2023) €1,500,000,000 MEDTRONIC, INC. €750,000,000 2.950% Senior Notes due 2030 €750,000,000 4.200% Senior Notes due 2045 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC GLOBAL HOLDINGS S.C.A. Medtronic, Inc., a Minnesota corporation (

UNDERWRITING AGREEMENT MEDTRONIC, INC. 2.950% Senior Notes due 2030 4.200% Senior Notes due 2045 Underwriting Agreement

EX-1.1 Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT €1,500,000,000 MEDTRONIC, INC. 2.950% Senior Notes due 2030 4.200% Senior Notes due 2045 Underwriting Agreement September 15, 2025 Deutsche Bank AG, London Branch Goldman Sachs & Co. LLC c/o Deutsche Bank AG, London Branch 21 Moorfields London EC2Y 9DB United Kingdom c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Uni

Subject to Completion, dated September 15, 2025

424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-270272-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sa

Medtronic, Inc. Pricing Term Sheet September 15, 2025 Issuer: Medtronic, Inc. Guarantors: Medtronic plc and Medtronic Global Holdings S.C.A. Trade Date: September 15, 2025 Settlement Date*: T+10; September 29, 2025 Denominations: €100,000 x €1,000 Li

FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-270272-01 September 15, 2025 Medtronic, Inc. Pricing Term Sheet September 15, 2025 Issuer: Medtronic, Inc. Guarantors: Medtronic plc and Medtronic Global Holdings S.C.A. Trade Date: September 15, 2025 Settlement Date*: T+10; September 29, 2025 Denominations: €100,000 x €1,000 Listing: Issuer intends to apply to l

ARS

)LVFDO
D7BADF
BGDEG3@F
FA
E75F;A@

AD
6
A8
F:7
+75GD;F;7E
J5:3@97
5F
A8
 AD
F:7
8;E53>
K73D
7@676
BD;>


,D3@E;F;A@
D7BADF
BGDEG3@F
FA
+75F;A@

AD
6
A8
F:7
+75GD; F;7E
J5:3@97
5F
A8
 AD
F:7
FD3@E;F;A@
B7D;A6
8DA?
2222222222
FA
2222222222 A??;EE;A@
;>7
&A
  S %76FDA@;5
B>5  M68I
C6B:
D;
G:<>HIG6CI
6H
HE:8>;>:9
>C
>IH
8=6GI:G !D7>3@6   .

144

144 0001708062 XXXXXXXX LIVE 0001613103 Medtronic plc 001-36820 BUILDING TWO PARKMORE BUSINESS PARK WEST GALWAY L2 H91 4K49 01135314381700 KIIL HARRY SKIP Officer Common Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 8605 788048.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 25, 2025 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 25, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy State

Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating commi

Exhibit 99.2 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities Experienced executives John Groetelaars and Bill Jellison appointed to the Board of Directors Board forms new Growth and Operating committees to sharpen focus on the company's ongoing strategic portfolio management, operational execution

Medtronic reports first quarter fiscal 2026 financial results 11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2026 financial results 11th quarter in a row of mid-single digit organic revenue growth; Poised to accelerate growth GALWAY, Ireland – August 19, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 (FY26), wh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Medtronic plc (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☒ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the gaurantor of the stated securities from listing and registration on the Exchange at the opening of business on July 14, 2025, pursuant to the provisions of Rule 12d2-2 (a).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

Medtronic Board appoints Dr. Joon Lee as a new director

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Dr.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 25, 2025. ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 25, 2025. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ® Medtronic plc (Exact name of reg

Medtronic plc Policy For The Recovery of Erroneously Awarded Compensation

Exhibit 97 MEDTRONIC PLC POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Description Medtronic plc, an Irish public limited company (the “Company”) has adopted this Policy for the Recovery of Erroneously Awarded Compensation (the “Policy”), pursuant to the requirements of the New York Stock Exchange listing standards and Exchange Act Rule 10D-1.

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

Medtronic Nonqualified Retirement Plan Supplement

2025 MEDTRONIC NONQUALIFIED RETIREMENT PLAN SUPPLEMENT (as amended and restated effective March 3, 2025) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT Section 1.

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 25, 2025 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Description of Registrant's Securities

Exhibit 4.30 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of Medtronic plc, a company incorporated under the laws of Ireland (“Medtronic” or “Medtronic plc”), (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 3.000% Se

Medtronic plc Global Insider Trading Policy

Exhibit 19 Global Insider Trading Policy Purpose The U.S. Securities and Exchange Commission (SEC) and other government bodies created rules to prevent unethical use of nonpublic information. This policy outlines the requirements employees must follow to comply with these rules and applicable laws. Scope This policy applies to all Medtronic employees and members of the Board of Directors. Policy S

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2024 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2024 to December 31, 2024 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Building Two, Parkmore Business Park West Galway, Ireland n/a (Address of principal exec

Medtronic announces intent to separate Diabetes business Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; o

Exhibit 99.2 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic announces intent to separate Diabetes business Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland – May 21

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuro

Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland – May 21, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare t

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 24, 2025 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 24, 2025 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Letter Agreement by and between Medtronic, Inc. and Thierry Piéton dated December 24, 2024

Medtronic, Inc. 710 Medtronic Parkway, LC210 Minneapolis, MN 55432-5604 USA Tel: 1.763.514.4000 www.medtronic.com December 24, 2024 Mr. Thierry Pieton Dear Thierry, I am pleased to provide you with this offer of employment at Medtronic. Your valuable experience will help shape our business and improve the lives of patients. Building the right team of talented people plus our market-leading positio

Medtronic reports third quarter fiscal 2025 financial results Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2025 financial results Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland – Feb. 18,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

Medtronic appoints Thierry Piéton as Chief Financial Officer

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic appoints Thierry Piéton as Chief Financial Officer GALWAY, Ireland – Date – Jan.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 25, 2024 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 25, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

LETTER

November 21, 2024 Jennifer Kirk Senior Vice President, Global Controller and Chief Accounting Officer Medtronic plc Building Two, Parkmore Business Park West Galway, Ireland Re: Medtronic plc Form 10-K for Fiscal Year Ended April 26, 2024 Filed June 20, 2024 File No.

Medtronic reports second quarter fiscal 2025 financial results Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spin

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2025 financial results Delivering on commitments, executing ahead of expectations, and raising guidance Innovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabet

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic plc

Medtronic plc Building Two Parkmore Business Park West Galway, Ireland www.medtronic.com November 18, 2024 Via EDGAR Correspondence Mr. Michael Fay United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Mail Stop 3030 Washington, DC 20549 Re: Medtronic plc Form 10-K for the Fiscal Year Ended April 26, 2024 Filed June 20, 2024 File No. 001-36820 Dear Mr. Fay

LETTER

November 13, 2024 Jennifer Kirk Senior Vice President, Global Controller and Chief Accounting Officer Medtronic plc Building Two, Parkmore Business Park West Galway, Ireland Re: Medtronic plc Form 10-K for Fiscal Year Ended April 26, 2024 Filed June 20, 2024 File No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 26, 2024 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 26, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 Medtronic plc (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

Medtronic reports first quarter fiscal 2025 financial results Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablation, Pai

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2025 financial results Product innovation driving growth across diversified health tech portfolio, including Automated Insulin Delivery, Transcatheter Aortic Valve Replacement, Pulsed Field Cardiac Ablat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

Medtronic announces departure of Karen Parkhill, Chief Financial Officer

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic announces departure of Karen Parkhill, Chief Financial Officer DUBLIN, June 26, 2024 - / PRNewswire / - Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and chief financial officer to accept the role of chief financial officer for HP Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 26, 2024. ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 26, 2024. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ® Medtronic plc (Exact name of reg

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 26, 2024 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

Medtronic plc Global Insider Trading Policy

Exhibit 19 Global Insider Trading Policy Purpose The U.S. Securities and Exchange Commission (SEC) and other government bodies created rules to prevent unethical use of nonpublic information. This policy outlines the requirements employees must follow to comply with these rules and applicable laws. Scope This policy applies to all Medtronic employees and members of the Board of Directors. Policy S

Description of Registrant's Securities

Exhibit 4.30 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of Medtronic plc, a company incorporated under the laws of Ireland (“Medtronic” or “Medtronic plc”), (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 3.000% Se

Medtronic plc Policy For The Recovery of Erroneously Awarded Compensation

Exhibit 97 MEDTRONIC PLC POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Description Medtronic plc, an Irish public limited company (the “Company”) has adopted this Policy for the Recovery of Erroneously Awarded Compensation (the “Policy”), pursuant to the requirements of the New York Stock Exchange listing standards and Exchange Act Rule 10D-1.

NYSE CERTIFICATION

New York Stock Exchange 11 Wall Street New York, NY 10005 Tel: +1 212.656.3000 nyse.com June 6, 2024 Chief, Information Technology Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE MS 3040 Washington, DC 20549 To whom it may concern: The New York Stock Exchange certifies its approval for listing and registration of the following securities of Medtronic, Inc., guaran

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Opinion of CM Law, Luxembourg counsel to Medtronic Global Holdings S.C.A.

EX-5.3 Exhibit 5.3   To: Medtronic Global Holdings S.C.A. 40, avenue Monterey, L-2163 Luxembourg (the “Addressee”) By e-mail Luxembourg, 3 June 2024 Re.: Medtronic Global Holdings S.C.A. acting through its managing general partner Medtronic Global Holdings GP S.à r.l. Dear Sirs, I. Introduction We have been appointed as legal counsel in the Grand Duchy of Luxembourg (“Luxembourg”) in order to prov

Agency Agreement, dated as of June 3, 2024, between Medtronic, Inc., Computershare Trust Company, N.A., as trustee, Elavon Financial Services DAC, UK Branch, as paying agent, and U.S. Bank National Association, as transfer agent and registrar

EX-4.6 Exhibit 4.6 DATED JUNE 3, 2024 ISSUER MEDTRONIC, INC. PAYING AGENT ELAVON FINANCIAL SERVICES DAC, UK BRANCH TRANSFER AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. REGISTRAR U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION. - AND - TRUSTEE COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT relating to certain Notes issued under a supplemental indenture dated June 3, 2024

Underwriting Agreement, dated as of May 29, 2024, among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., and Citigroup Global Markets Limited, J.P. Morgan Securities plc, Merrill Lynch International and Mizuho International plc, as representatives of the several underwriters named therein.

EX-1.1 Exhibit 1.1 EXECUTION VERSION UNDERWRITING AGREEMENT €3,000,000,000 MEDTRONIC, INC. 3.650% Senior Notes due 2029 3.875% Senior Notes due 2036 4.150% Senior Notes due 2043 4.150% Senior Notes due 2053 Underwriting Agreement May 29, 2024 Citigroup Global Markets Limited J.P. Morgan Securities plc Merrill Lynch International Mizuho International plc c/o Citigroup Global Markets Limited Citigro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic, Inc. (Exact name of registrant as

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic, Inc. (Exact name of registrant as specified in its charter) Minnesota 41-0793183 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification N

Fifth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of June 3, 2024, among Medtronic, Inc., Medtronic plc, Medtronic Global Holdings S.C.A., Computershare Trust Company, N.A., as trustee, and Elavon Financial Services DAC, UK Branch (incorporated by reference to Exhibit 4.1 to Medtronic plc’s Form 8-K, filed on June 3, 2024)

EX-4.1 Exhibit 4.1 MEDTRONIC, INC. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC GLOBAL HOLDINGS S.C.A. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee, and ELAVON FINANCIAL SERVICES DAC, UK BRANCH, as Paying Agent FIFTH SUPPLEMENTAL INDENTURE Dated as of June 3, 2024 TO THE INDENTURE Dated as of December 10, 2014 Rela

Consent of Thomas L. Osteraas, Legal Director - Corporate & Securities of Medtronic, Inc. (included in Exhibit 5.4).

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com June 3, 2024 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic, Inc Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic, Inc., a Minnesota corporation (the “Company”) of €850,000,000 aggregate principal amount of

Calculation of Filing Fee Tables (Form Type) MEDTRONIC, INC. MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC GLOBAL HOLDINGS S.C.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: MEDTRONIC, INC.

€3,000,000,000 MEDTRONIC, INC. €850,000,000 3.650% Senior Notes due 2029 €850,000,000 3.875% Senior Notes due 2036 €600,000,000 4.150% Senior Notes due 2043 €700,000,000 4.150% Senior Notes due 2053 Fully and Unconditionally Guaranteed by MEDTRONIC P

Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-270272-01 PROSPECTUS SUPPLEMENT (To Prospectus dated March 3, 2023) €3,000,000,000 MEDTRONIC, INC. €850,000,000 3.650% Senior Notes due 2029 €850,000,000 3.875% Senior Notes due 2036 €600,000,000 4.150% Senior Notes due 2043 €700,000,000 4.150% Senior Notes due 2053 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC

Medtronic, Inc. Pricing Term Sheet May 29, 2024 Issuer: Medtronic, Inc. Guarantors: Medtronic plc and Medtronic Global Holdings S.C.A. Trade Date: May 29, 2024 Settlement Date*: T+3; June 3, 2024 Denominations: €100,000 x €1,000 Listing: Issuer inten

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-270272-01 May 29, 2024 Medtronic, Inc. Pricing Term Sheet May 29, 2024 Issuer: Medtronic, Inc. Guarantors: Medtronic plc and Medtronic Global Holdings S.C.A. Trade Date: May 29, 2024 Settlement Date*: T+3; June 3, 2024 Denominations: €100,000 x €1,000 Listing: Issuer intends to apply to list the Notes on the New York

Subject to Completion, dated May 29, 2024

Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-270272-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2023 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2023 to December 31, 2023 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of principal executive of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structural Hear

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Broad-based, durable growth across the company, including Cranial & Spinal Technologies, Diabetes, Cardiac Pacing, Surgical, and Structu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 26, 2024 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 26, 2024 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Medtronic reports third quarter fiscal 2024 financial results Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S.

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2024 financial results Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

OBIO / Orchestra BioMed Holdings, Inc. / Medtronic plc - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 mdt20240213sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Orchestra BioMed Holdings, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 68572M106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)

MDT / Medtronic plc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01437-medtronicplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Medtronic PLC Title of Class of Securities: Common Stock CUSIP Number: G5960L103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rul

MDT / Medtronic plc / BlackRock Inc. Passive Investment

ie00btn1y115021224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) MEDTRONIC PUBLIC LIMITED COMPANY - (Name of Issuer) Common Stock - (Title of Class of Securities) BTN1Y11 - (SEDOL Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

As filed with the Securities and Exchange Commission on December 8, 2023

As filed with the Securities and Exchange Commission on December 8, 2023 Registration No.

Power of

Exhibit 24.1 POWER OF ATTORNEY RELATING TO REGISTRATION STATEMENT ON FORM S-8 FOR MEDTRONIC PLC 2024 EMPLOYEE STOCK PURCHASE PLAN We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Ivan K. Fong and Courtney Nelson Wills, and each of them singly, with full and several power of substitution and resubstitution and to act with or without the others, fo

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Medtronic plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate (1) Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration fee Equity Ordinary Shares, par v

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 27, 2023 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 27, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports second quarter fiscal 2024 financial results Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises fiscal ye

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2024 financial results Solid execution results in mid-single digit revenue growth, driven by broad-based strength across multiple businesses and geographies; Major innovative product approvals; Raises f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

Medtronic plc 2024 Employee Stock Purchase Plan

MEDTRONIC PLC 2024 EMPLOYEE STOCK PURCHASE PLAN 1.Purpose of Plan. Medtronic plc (hereinafter referred to as the “Company”) proposes to grant to Employees of the Company and of certain of its Subsidiaries the opportunity to purchase ordinary shares of the Company. Such ordinary shares shall be purchased pursuant to this Plan, which is the MEDTRONIC PLC 2024 EMPLOYEE STOCK PURCHASE PLAN (hereinafte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

ARS

FiscalYear2023/ Geoff Martha Chairman & CEO August 31, 2023 Dear Shareholders, Alleviate pain.

ualified Stock Option Agreement 2021 Medtronic plc Long Term Incentive Plan

MEDTRONIC plc NON-QUALIFIED STOCK OPTION AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Shares Awarded: Expiration Date: 1.

Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan

MEDTRONIC plc RESTRICTED STOCK UNIT AWARD AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Shares Awarded: 1.

Restricted Stock Unit Award Agreement 2021 Medtronic plc Long Term Incentive Plan

MEDTRONIC plc RESTRICTED STOCK UNIT AWARD AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Shares Awarded: 1.

Performance Share

MEDTRONIC plc PERFORMANCE SHARE UNIT AWARD AGREEMENT 2021 MEDTRONIC PLC LONG TERM INCENTIVE PLAN Name: Employee ID: Client Grant ID: Grant Date: Grant Price: Grant Type: Target PERFORMANCE SHARE UNITS: Performance Period: FY2023 to FY2025 (“Performance Period”) 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 28, 2023 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 28, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

Medtronic reports first quarter fiscal 2024 financial results Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2024 financial results Broad strength across businesses and geographies results in mid-single digit revenue growth, driven by execution, innovation, and improved underlying fundamentals DUBLIN – Aug. 22,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ☐ Definitive Proxy State

Medtronic Board appoints Greg Lewis as new Director

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Greg Lewis as new Director DUBLIN, June 26, 2023 - Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the Board.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 28, 2023. ☐ Transition report pursuant to Sectio

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 28, 2023. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ® Medtronic plc

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

Medtronic Nonqualified Retirement Plan Supplement dated as of April 28, 2023

MEDTRONIC NONQUALIFIED RETIREMENT PLAN SUPPLEMENT (as amended and restated effective April 28, 2023) TABLE OF CONTENTS ARTICLE 1 DEFERRED COMPENSATION ACCOUNT.

Description of Registrant's Securities

Exhibit 4.25 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of Medtronic plc, a company incorporated under the laws of Ireland (“Medtronic” or “Medtronic plc”), and (ii) the 0.250% Senior Notes due 2025, 0.000% Senior Notes due 2025, 2.625% Senior Notes due 2025, 1.125% Senior Notes due 2027, 0.375% Senior Notes due 2028, 1.625

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 28, 2023 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Amendment No. 2 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2020

AMENDMENT NO. 2 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 12, 2020 AMENDMENT NO. 2 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) among MEDTRONIC GLOBAL HOLDINGS S.C.A., a partnership limited by shares (société en commandite par actions) incorporated under the laws of the Grand-Duchy of Luxembourg having its r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of principal executive of

Conflict Minerals Report of the Company

Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2022 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2022 to December 31, 2022 (the “Reporting Period”) pursuant to Rule 13p-1 and Form SD (the “Rule”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Medtronic plc (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase Mid-single digit fourth quarter revenue growth exceeded expectations on broad-based strength across the company DUBLIN – May 25, 2023 –

Opinion of DLA Piper, Luxembourg counsel to Medtronic Global Holdings S.C.A.

EX-5.3 Exhibit 5.3 DLA Piper Luxembourg 37A, Avenue John F. Kennedy L-1855 Luxembourg T +352 26 29 04 2052 F +352 26 29 04 3000 W www.dlapiper.com Medtronic Global Holdings S.C.A. Our reference 40, avenue Monterey LM/CN/410009/1 L-2163 Luxembourg Grand Duchy of Luxembourg (“Addressee” or “you”) March 30, 2023 By Courier and E-mail Dear Sir, Dear Madam, 1. ROLE OF DLA PIPER LUXEMBOURG 1.1 DLA Piper

Consent of Thomas L. Osteraas, Legal Director - Corporate and Securities of Medtronic, Inc. (included in Exhibit 5.4).

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com March 30, 2023 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic Global Holdings S.C.A. Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic Global Holdings S.C.A, an entity organized under the laws of Luxembourg (

Underwriting Agreement, dated as of March 23, 2023, among Medtronic Global Holdings S.C.A., Medtronic plc and Medtronic, Inc., and Barclays Capital Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein.

EX-1.1 Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT $2,000,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. 4.250% Senior Notes due 2028 4.500% Senior Notes due 2033 Underwriting Agreement March 23, 2023 Barclays Capital Inc. J.P. Morgan Securities LLC Mizuho Securities USA LLC c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 c/o J.P. Morgan Securities LLC 383 Madison Avenue N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Medtronic plc (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

Seventh Supplemental Indenture, dated as of March 30, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (including the forms of the 2028 Notes and the 2033 Notes).

EX-4.2 Exhibit 4.2 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee SEVENTH SUPPLEMENTAL INDENTURE DATED AS OF MARCH 30, 2023 TO INDENTURE DATED AS OF MARCH 28, 2017 Relating to $1,000,000,000 4.250% Senior Notes due 2028 $1,000,000,000

Calculation of Filing Fee Tables (Form Type) MEDTRONIC GLOBAL HOLDINGS S.C.A. MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: MEDTRONIC GLOBAL HOLDINGS S.

Medtronic Global Holdings S.C.A. Pricing Term Sheet March 23, 2023 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: March 23, 2023 Settlement Date*: T+5; March 30, 2023 Denominations: $2,000 x $1,000

FWP 1 d460820dfwp.htm FWP Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-270272 March 23, 2023 Medtronic Global Holdings S.C.A. Pricing Term Sheet March 23, 2023 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: March 23, 2023 Settlement Date*: T+5; March 30, 2023 Denominations: $2,000 x $1,000 Expected Ratings (Mo

$2,000,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. $1,000,000,000 4.250% Senior Notes due 2028 $1,000,000,000 4.500% Senior Notes due 2033 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC.

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-270272 PROSPECTUS SUPPLEMENT (To Prospectus dated March 3, 2023) $2,000,000,000 ® MEDTRONIC GLOBAL HOLDINGS S.C.A. $1,000,000,000 4.250% Senior Notes due 2028 $1,000,000,000 4.500% Senior Notes due 2033 Fully and Unconditionally Guaranteed by MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. Medtronic Global Hold

Subject to Completion, dated March 23, 2023

424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-270272 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the stated securities from listing and registration on the Exchange at the opening of business on March 27, 2023, pursuant to the provisions of Rule 12d2-2 (a).

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the entire class of the stated securities from listing and registration on the Exchange at the opening of business on March 21, 2023, pursuant to the provisions of Rule 12d2-2 (a).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Medtronic plc (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the Trustee under the Medtronic, Inc. Senior Indenture

EX-25.3 Exhibit 25.3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

Fourth Supplemental Indenture to Medtronic, Inc. Senior Indenture, dated as of February 22, 2023 among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc and Computershare Trust Company, N.A. (as successor to Wells Fargo Bank, National Association), as trustee

EX-4.9 Exhibit 4.9 MEDTRONIC INC. and COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee FOURTH SUPPLEMENTAL INDENTURE DATED AS OF FEBRUARY 22, 2023 TO INDENTURE DATED AS OF DECEMBER 10, 2014 FOURTH SUPPLEMENTAL INDENTURE, dated as of February 22, 2023 (the “Supplemental Indenture”), to the Base Indenture (defined below) between MEDTRONIC, INC., a

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MEDTRONIC PUBLIC LIMITED COMPANY (Exact Name of Registrant as Specified in its Charter) MEDTRONIC GLOBAL HOLDINGS S.

The Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939, as amended, of the Trustee under the Senior Indenture of Medtronic Global Holdings S.C.A.

EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its ch

Medtronic plc Powers of Attorney

EX-24.1 Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of Medtronic plc, hereby severally constitute and appoint Ivan Fong and Martha Ha, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-3 filed herewith

Sixth Supplemental Indenture, dated as of February 22, 2023, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, and Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee (incorporated by reference to Exhibit 4.2 to Medtronic plc’s Registration Statement on Form S-3, filed on March 3, 2023, File No. 333-270272).

EX-4.2 Exhibit 4.2 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors, and COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee SIXTH SUPPLEMENTAL INDENTURE DATED AS OF FEBRUARY 22, 2023 TO INDENTURE DATED AS OF MARCH 28, 2017 SIXTH SUPPLEMENTAL INDENTURE, dated as of February 22, 2023 (the

Opinion of DLA Piper Luxembourg S.à r.l., Luxembourg counsel to Medtronic Global Holdings S.C.A. and Medtronic Global Holdings GP S.à r.l.

EX-5.3 Exhibit 5.3 Medtronic Global Holdings S.C.A. 40, avenue Monterey L-2163 Luxembourg Grand Duchy of Luxembourg in its capacity as Issuer (as defined below) Your reference Our reference LM/CN LU/410009/53 (“Addressee” or “you”) March 3, 2023 By Courier and E-mail Dear Sirs, REGISTRATION-FILING TO THE U.S. SECURITIES AND EXCHANGE COMMISSION – MEDTRONIC GLOBAL HOLDINGS S.C.A. 1. ROLE OF DLA PIPE

Consent of Thomas L. Osteraas, Legal Director – Corporate and Securities of Medtronic, Inc. (included in Exhibit 5.4)

EX-5.4 Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com March 3, 2023 Re: Registration Statement on Form S-3 Ladies and Gentlemen: This opinion is furnished to you in connection with a Registration Statement on Form S-3 (the “Registration Statement”) filed by Medtronic, Inc., a Minnesota corporation (the “Company”), Medtronic Public Limited Company, a public

Form of Subordinated Indenture of Medtronic Global Holdings S.C.A. (including form of Note and Guarantee)

EX-4.4 Exhibit 4.4 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer and MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors TO , as Trustee SUBORDINATED INDENTURE Dated as of TABLE OF CONTENTS* Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 10 Section 1.03 Form of Documents Delivered to

As filed with the Securities and Exchange Commission on March 3, 2023

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 3, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 27, 2023 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 27, 2023 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022.

EXECUTION COPY AMENDMENT NO. 4 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 12, 2022 AMENDMENT NO. 4 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) among MEDTRONIC GLOBAL HOLDINGS S.C.A., a partnership limited by shares (société en commandite par actions) incorporated under the laws of the Grand-Duchy of Luxembou

Annex I to Amendment No. 4 and Extension Agreement to the Amended and Restated Credit Agreement dated as of December 12, 2022.

ANNEX I TO AMENDMENT NO. 4 AND EXTENSION AGREEMENT TO THE AMENDED AND RESTATED CREDIT AGREEMENT DATED AS OF DECEMBER 12, 2022 EXECUTION COPY Conformed for Amendment No. 2 and Extension Agreement dated as of December 12, 2020 and Amendment No. 3 and Extension Agreement dated as of December 13, 2021 Published CUSIP Number: Deal L7000JAA8 Revolver L7000JAB6 AMENDED AND RESTATED CREDIT AGREEMENT ($3,5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2023 financial results Delivers top and bottom line ahead of expectations, with strength in Cardiovascular and Neuroscience portfolios DUBLIN – Feb.

MDT / Medtronic PLC / BlackRock Inc. Passive Investment

ie00btn1y115021523.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) MEDTRONIC PUBLIC LIMITED COMPANY - (Name of Issuer) Common Stock - (Title of Class of Securities) BTN1Y11 - (SEDOL Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule

MDT / Medtronic PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01403-medtronicplc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Medtronic plc Title of Class of Securities: Common Stock CUSIP Number: G5960L103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rul

OBIO / Orchestra BioMed Holdings Inc / Medtronic plc - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Orchestra BioMed Holdings, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 68572M106 (CUSIP Number) January 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Medtronic plc (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the guarantor of the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 13, 2022, pursuant to the provisions of Rule 12d2-2 (a).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 28, 2022 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 28, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Medtronic plc (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numbe

Medtronic reports second quarter fiscal 2023 financial results Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2023 financial results Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (mark one) x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 1-36820 A. Full title of the plan and the address of the plan, if different

Opinion of DLA Piper, Luxembourg counsel to Medtronic Global Holdings S.C.A.

Exhibit 5.3 DLA Piper Luxembourg 37A, Avenue John F. Kennedy L-1855 Luxembourg T +352 26 29 04 2052 F +352 26 29 04 3000 W www.dlapiper.com Medtronic Global Holdings S.C.A. 40 avenue Monterey L-2163 Luxembourg Grand Duchy of Luxembourg Our reference LM/CN LU/410009/33 (?Addressee? or ?you?) September 21, 2022 By Courier and E-mail Dear Sir Dear Madam 1. ROLE OF DLA PIPER LUXEMBOURG 1.1 DLA Piper L

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 Medtronic plc (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Numb

DATED SEPTEMBER 21, 2022 MEDTRONIC GLOBAL HOLDINGS S.C.A. PAYING AGENT ELAVON FINANCIAL SERVICES DAC TRANSFER AGENT U.S. BANK TRUST COMPANY, N.A. U.S. BANK TRUST COMPANY, N.A. - AND - COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT

Exhibit 4.3 DATED SEPTEMBER 21, 2022 ISSUER MEDTRONIC GLOBAL HOLDINGS S.C.A. PAYING AGENT ELAVON FINANCIAL SERVICES DAC TRANSFER AGENT U.S. BANK TRUST COMPANY, N.A. REGISTRAR U.S. BANK TRUST COMPANY, N.A. - AND - TRUSTEE COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION AGENCY AGREEMENT relating to certain Notes issued under a supplemental indenture dated September 21, 2022 CONTENTS CLAUSE PAGE 1.

NYSE CERTIFICATION

New York Stock Exchange 11 Wall Street New York, NY 10005 Tel: +1 212.656.3000 nyse.com September 21, 2022 Chief, Information Technology Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE MS 3040 Washington, DC 20549 To whom it may concern: The New York Stock Exchange certifies its approval for listing and registration of the following securities of Medtronic Global

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic Global Holdings S.C.A. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Medtronic Global Holdings S.C.A. (Exact name of registrant as specified in its charter) Luxembourg 98-1202865 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Ident

Underwriting Agreement, dated as of September 15, 2022, among Medtronic Global Holdings S.C.A., Medtronic plc and Medtronic, Inc., and Barclays Bank PLC, BofA Securities Europe SA, Citigroup Global Markets Limited and HSBC Continental Europe, as representatives of the several underwriters named therein.

Exhibit 1.1 UNDERWRITING AGREEMENT ?3,500,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. 2.625% Senior Notes due 2025 3.000% Senior Notes due 2028 3.125% Senior Notes due 2031 3.375% Senior Notes due 2034 Underwriting Agreement September 15, 2022 Barclays Bank PLC BofA Securities Europe SA Citigroup Global Markets Limited HSBC Continental Europe Academy Securities, Inc. R. Seelaus & Co., LLC Samuel A. R

Consent of Thomas L. Osteraas, Principal Legal Counsel, Corporate & Securities of Medtronic, Inc. (included in Exhibit 5.4).

Exhibit 5.4 Medtronic, Inc. 710 Medtronic Parkway Minneapolis MN 55432 www.medtronic.com September 21, 2022 Medtronic, Inc. 710 Medtronic Parkway Minneapolis, MN 55432 Re: Medtronic Global Holdings S.C.A. Senior Notes Ladies and Gentlemen: This opinion is furnished to you in connection with the offer and sale by Medtronic Global Holdings S.C.A, an entity organized under the laws of Luxembourg (?Me

Fifth Supplemental Indenture, dated as of September 21, 2022, among Medtronic Global Holdings S.C.A., Medtronic, Inc. and Medtronic plc, Computershare Trust Company, N.A., as successor to Wells Fargo Bank, N.A., as trustee, and Elavon Financial Services DAC, as paying agent (including the forms of the 2025 Notes, the 2028 Notes, the 2031 Notes and the 2034 Notes).

Exhibit 4.1 MEDTRONIC GLOBAL HOLDINGS S.C.A. as Issuer, MEDTRONIC PUBLIC LIMITED COMPANY and MEDTRONIC, INC. as Guarantors, COMPUTERSHARE TRUST COMPANY, N.A. as successor to WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee, and ELAVON FINANCIAL SERVICES DAC, as Paying Agent FIFTH SUPPLEMENTAL INDENTURE DATED AS OF SEPTEMBER 21, 2022 TO INDENTURE DATED AS OF MARCH 28, 2017 Relating to ?500,000,00

€3,500,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. €500,000,000 2.625% Senior Notes due 2025 €1,000,000,000 3.000% Senior Notes due 2028 €1,000,000,000 3.125% Senior Notes due 2031 €1,000,000,000 3.375% Senior Notes due 2034 Fully and Unconditionally Gu

Table of Contents Filed pursuant to Rule 424(b)(5) Registration File No. 333-236739 PROSPECTUS SUPPLEMENT (To Prospectus dated February 28, 2020) ?3,500,000,000 MEDTRONIC GLOBAL HOLDINGS S.C.A. ?500,000,000 2.625% Senior Notes due 2025 ?1,000,000,000 3.000% Senior Notes due 2028 ?1,000,000,000 3.125% Senior Notes due 2031 ?1,000,000,000 3.375% Senior Notes due 2034 Fully and Unconditionally Guaran

Calculation of Filing Fee Tables (Form Type) MEDTRONIC GLOBAL HOLDINGS S.C.A. MEDTRONIC PUBLIC LIMITED COMPANY MEDTRONIC, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Issuer: MEDTRONIC GLOBAL HOLDINGS S.

Medtronic Global Holdings S.C.A. Pricing Term Sheet September 15, 2022 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: September 15, 2022 Settlement Date*: September 21, 2022 Denominations: €100,000

Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-236739 September 15, 2022 Medtronic Global Holdings S.C.A. Pricing Term Sheet September 15, 2022 Issuer: Medtronic Global Holdings S.C.A. Guarantors: Medtronic plc and Medtronic, Inc. Trade Date: September 15, 2022 Settlement Date*: September 21, 2022 Denominations: ?100,000 x ?1,000 Listing: Issuer intends to apply

Subject to Completion, dated September 15, 2022

Table of Contents Filed pursuant to Rule 424(b)(3) Registration File No. 333-236739 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not

Letter Agreement by and between Medtronic, Inc. and Ivan K. Fong dated November 19, 2021

Office of Chairman and Chief Executive Officer Medtronic, Inc. 710 Medtronic Parkway, LC210 Minneapolis, MN 55432-5604 USA Tel: 1.763.514.4000 www.medtronic.com November 19, 2021 Dear Ivan, I am pleased to provide you with this offer of employment at Medtronic (the Company). Your valuable experience and expertise will help shape our business and improve the lives of patients. Building the right te

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ☐ Transition report pursuant to Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 29, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number)

Medtronic reports first quarter fiscal 2023 financial results Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe

NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2023 financial results Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the app

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the app

DEF 14A 1 d382106ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (

Medtronic Board appoints Lidia Fonseca as a new director

CONTACTS Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Lidia Fonseca as a new director DUBLIN ? June 27, 2022 ? Medtronic plc (NYSE:MDT) today announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ☐ Transition report pursuant to Sectio

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to Commission File No. 1-36820 ? Medtronic plc

List of Senior Notes, Issuers and Guarantors.

Exhibit 22 Senior Notes, Issuers and Guarantors Registered Senior Notes Issued Under Issuer Guarantors Indenture, dated as of October 22, 2007 Covidien International Finance S.

List of Subsidiaries of Medtronic plc.

Exhibit 21 Medtronic plc and Subsidiaries At April 29, 2022 Company Jurisdiction of Formation 2074417 Alberta ULC Canada A&E Products de Honduras S.

Description of Registrant's Securities

Exhibit 4.25 The following is a brief description of (i) the ordinary shares, par value $0.0001 per share (the ?Ordinary Shares?), of Medtronic plc, a company incorporated under the laws of Ireland (?Medtronic? or ?Medtronic plc?), and (ii) the 0.000% Senior Notes due 2022, 0.375% Senior Notes due 2023, 0.000% Senior Notes due 2023, 0.25% Senior Notes due 2025, 0.000% Senior Notes due 2025, 1.125%

Power of Attorney.

Exhibit 24 POWER OF ATTORNEY Each of the undersigned directors of Medtronic plc, an Irish public limited company, hereby constitutes and appoints each of IVAN K.

Conflict Minerals Report of the Company

EX-1.01 2 exhibit101-2021conflictmin.htm EX-1.01 Exhibit 1.01 Medtronic plc Conflict Minerals Report For the Year Ended December 31, 2021 Overview This Conflict Minerals Report (this “Report”) of Medtronic plc (“Medtronic,” the “Company,” “we,” “us,” and “our”) has been prepared by us on a consolidated basis for the reporting period from January 1, 2021 to December 31, 2021 (the “Reporting Period”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 20 On Hatch, Lower Hatch Street Dublin 2, Ireland n/a (Address of principal executive of

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Medtronic plc (Exact name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (I

Medtronic and DaVita announce new kidney health technology company Companies join forces to accelerate kidney care device innovation and improve patient outcomes

FOR IMMEDIATE RELEASE Medtronic and DaVita announce new kidney health technology company Companies join forces to accelerate kidney care device innovation and improve patient outcomes DUBLIN and DENVER ? May 26, 2022 ? Medtronic plc (NYSE: MDT) and DaVita Inc.

Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns

Exhibit 99.1 NEWS RELEASE Contacts: Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN ?

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 Medtronic Public Limited Company (Exact Name of Registrant as Specified in its Charter) Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commissi

Term Loan Agreement, dated as of May 2, 2022, by and among Medtronic Global Holdings S.C.A., Medtronic, Inc., Medtronic plc, and Mizuho Bank, Ltd., as administrative agent and as lender.

Exhibit 10.01 EXECUTION COPY ?300,000,000,000 TERM LOAN AGREEMENT dated as of May 2, 2022 among MEDTRONIC GLOBAL HOLDINGS S.C.A. as Borrower, and MEDTRONIC, INC. and MEDTRONIC PLC, as Guarantors, THE LENDERS PARTY HERETO, and MIZUHO BANK, LTD., as Administrative Agent TABLE OF CONTENTS Page Article I Definitions 1 Section 1.01. Defined Terms 1 Section 1.02. Terms Generally 15 Section 1.03. Account

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ☐ Transition report pursuant to Sectio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.